Discovering novel chemotherapeutic drugs for the third millennium (Q33859300)

29 July 2017

1 reference

title

Discovering novel chemotherapeutic drugs for the third millennium (English)

1 reference

29 July 2017

1 reference

Garrett MD

1

1 reference

29 July 2017

Workman P

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

European Journal of Cancer

29 July 2017

published in

1 reference

29 July 2017

volume

35

1 reference

29 July 2017

issue

14

1 reference

29 July 2017

page(s)

2010-2030

1 reference

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Conventional cancer therapy: promise broken or promise delayed?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Essential drugs for cancer therapy: a World Health Organization consultation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

1 reference

7 January 2021

Genetic pathways in colorectal and other cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The promise of cancer genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The promise of molecular oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Gene estimate rises as US and UK discuss freedom of access

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

New goals for the U.S. Human Genome Project: 1998-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Genomic sciences and the medicine of tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

DNA microarrays in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Proteomics: a major new technology for the drug discovery process

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Gene expression profiles in normal and cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Identifying small-molecule lead compounds: the screening approach to drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Drug screening--beyond the bottleneck

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Combinatorial chemistry in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Integrating Genetic Approaches into the Discovery of Anticancer Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Structural genomics: beyond the human genome project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Chemical genetics: exploring and controlling cellular processes with chemical probes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Structure-pharmacokinetic relationships for misonidazole analogues in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Development of quantitative structure-pharmacokinetic relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

In vivo cultivation of tumor cells in hollow fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Systems for Identifying New Drugs Are Often Faulty

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

What is the optimal rodent model for anti-tumor drug testing?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Orthotopic models are necessary to predict therapy of transplantable tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Non-invasive MRS in new anticancer drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Molecular imaging: exploring the next frontier

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Opportunities for pharmacological intervention in the ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

All ras proteins are polyisoprenylated but only some are palmitoylated

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The ras gene family and human carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The structure of Ras protein: a model for a universal molecular switch

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Creation of human tumour cells with defined genetic elements

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Essential role for oncogenic Ras in tumour maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Requirement for c-ras proteins during viral oncogene transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Pharmaceutical research in molecular oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibitors of prenyl transferases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Paradoxical activation of Raf by a novel Raf inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Effect of SB 203580 on the activity of c-Raf in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A synthetic inhibitor of the mitogen-activated protein kinase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Phosphoinositide 3-kinases: A conserved family of signal transducers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Akt is more than just a Bad kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cellular mechanisms of wingless/Wnt signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Mechanisms of Wnt signaling in development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The role of beta-catenin in cell adhesion, signal transduction, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The oncogenic activation of beta-catenin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Casein kinase I transduces Wnt signals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

APC: the plot thickens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Regulation of LEF-1/TCF transcription factors by Wnt and other signals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A retrovirus vector expressing the putative mammary oncogene int-1 causes partial transformation of a mammary epithelial cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Stabilization of beta-catenin by genetic defects in melanoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Tissue-specific expression of beta-catenin in normal mesenchyme and uveal melanomas and its effect on invasiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Principles of CDK regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Viewpoint: putting the cell cycle in order

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Evolving ideas about cyclins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Aberrations of the G1- and G1/S-regulating genes in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

1 reference

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Potent interaction of flavopiridol with MRP1

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

CDK inhibition and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Characterization of novel inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

An artificial cell-cycle inhibitor isolated from a combinatorial library

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Role of E2F in cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Differential regulation of E2F transactivation by cyclin/cdk2 complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Tossing monkey wrenches into the clock: new ways of treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Polo-like kinases: positive regulators of cell division from start to finish.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cancer progression and p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cancer. p53, guardian of the genome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The complexity of p53 modulation: emerging patterns from divergent signals

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

1 reference

7 January 2021

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Retrovirus-mediated p53 gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Reactivation of mutant p53: a new strategy for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

New p53-based anti-cancer therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Signaling to p53: breaking the MDM2-p53 circuit

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Size control in animal development

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Perspectives: cell biology. All creatures great and small

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Continuous protein synthesis is required to maintain the probability of entry into S phase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Translation factors as effectors of cell growth and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Translational control: the cancer connection

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The mRNA 5' cap-binding protein eIF4E and control of cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

PKR, apoptosis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Translational control of growth factor and proto-oncogene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Translation initiation: adept at adapting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Translation initiation factor 4E.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Protein synthesis initiation factor 4G.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

eIF4E activity is regulated at multiple levels

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Signal transduction pathways that regulate eukaryotic protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: increased cap affinity of the phosphorylated form

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The ubiquitin-proteasome pathway: on protein death and cell life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

1 reference

7 January 2021

The ubiquitin-proteasome pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The ubiquitin-proteasome pathway and pathogenesis of human diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Relationships between proteasomes and viral gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cancer prognostics: past, present and p27

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Lactacystin, Proteasome Function, and Cell Fate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Proteasome inhibitors: valuable new tools for cell biologists

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Cyclin E-CDK2 is a regulator of p27Kip1.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Chromatin remodeling and transcriptional regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Histone acetylases and deacetylases in cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Molecular chaperones: the busy life of Hsp90.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Inhibition of telomerase limits the growth of human cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

Telomeres: has cancer's Achilles' heel been exposed?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

For better or worse? Telomerase inhibition and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

eIF4E expression in tumors: its possible role in progression of malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900280-4

7 January 2021

10.1016/S0959-8049(99)00280-4

Identifiers

DOI

1 reference

29 July 2017

1 reference